119th Congress
H.R. 10628
Biosimilars Access and Affordability Act
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Nicholas A. Langworthy(R-NY)
- Introduced
- Sep 28, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce; House Committee on Ways and Means
- Official text
- Introduced in House · Congress.gov page
Cosponsors (8)
Original cosponsors (8)
- Jake Auchincloss (D-MA)
- Jimmy Panetta (D-CA)
- John Joyce (R-PA)
- Kevin Mullin (D-CA)
- Linda T. Sánchez (D-CA)
- Nathaniel Moran (R-TX)
- Rudy Yakym III (R-IN)
- Scott H. Peters (D-CA)
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Official title: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Latest action(Sep 28, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Roll-call votes
No recorded votes on this bill.
Actions
- Sep 28, 2026 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. - Sep 28, 2026
Introduced in House